ISL/LEN

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

HIV-1-InfectionHIV-1-infection

Phase 3

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

Active, not recruitingNCT06630299

Gilead SciencesHIV-1-Infection

Start: 2024-10-08End: 2030-08-31Target: 600Updated: 2025-11-14

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Active, not recruitingNCT06630286

Gilead SciencesHIV-1-infection

Start: 2024-10-09End: 2030-08-31Updated: 2025-11-13